Obesity drugs under siege

Technology Briefing

Interneuron Pharmaceuticals Inc.'s Redux dexfenfluramine is taking a growing beating in the scientific literature, as anecdotal evidence of significant side effects is starting to trickle in. Partner Wyeth-Ayerst last week scrambled to keep up, announcing that it is working with Mayo Clinic Researchers to evaluate any links between valvular heart disease and weight loss drugs...